We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sosei Group’s wholly-owned subsidiary Heptares Therapeutics and Takeda Pharmaceutical have signed an agreement to discover, develop and commercialise new molecules, including small molecules and biologics.